A carregar...
Construction and characterization of an anti-CD20 mAb nanocomb with exceptionally excellent lymphoma-suppressing activity
The CD20-directed monoclonal antibody rituximab (RTX) established a new era in the treatment of non-Hodgkin lymphoma (NHL); however, suboptimal response and/or resistance to RTX still limit its clinical merits. Although four effector mechanisms are validated to participate in CD20-based immunotherap...
Na minha lista:
| Publicado no: | Int J Nanomedicine |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4525799/ https://ncbi.nlm.nih.gov/pubmed/26257518 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/IJN.S80129 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|